Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients
Open Access
- 2 September 2026
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e015414
Abstract
Background: Immune checkpoint inhibitors (ICIs) have limited efficacy in proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC). However, selected patients with specific metastatic patterns may derive benefit. Methods: Patients with chemorefractory pMMR/MSS mCRC treated with ICI-based regimens were retrospectively identified. A comparison cohort treated with trifluridine/tipiracil±bevacizumab, regorafenib, or fruquintinib as standard of care (SOC) was generated through 1:1 propensity score matching by age, sex, Eastern Cooperative Oncology Group performance status (ECOG PS), liver metastases (present/absent), and RAS/BRAF status. Overall survival (OS) was compared using Cox regression. Results: A total of 354 patients treated with ICIs and 354 treated with SOC were matched. Median age was 55 years, 52% male, 32% ECOG PS 0, 30% right-sided, and 69% RAS mutated in both groups, while 61% and 60% had liver metastases, respectively. Median OS (mOS) was 10.8 months with ICIs and 9.0 months with SOC (HR 0.76, 95% CI 0.64 to 0.92, p=0.004). In patients without liver metastases, mOS was longer with ICIs than SOC (19.1 vs 13.2 months, HR 0.59, 95% CI 0.43 to 0.80, pRAS / BRAF status were not associated with OS. Treatment with ICIs, absence of liver metastases, one prior line of therapy, less than three metastatic sites, and ECOG PS 0 were associated with the most favorable outcomes in univariable and multivariable models. Conclusions: In chemorefractory pMMR/MSS mCRC without liver metastases, ICI-based regimens yielded longer OS than SOC. Further investigation of ICIs in this patient population is warranted.Keywords
Funding Information
- The Andrew Sabin Family Fellowship Award at The University of Texas MD Anderson Cancer Center (N/A)
- Col. Daniel Connelly Memorial Fund (N/A)
- the National Cancer Institute Cancer Center Support Grant (P30 CA016672)
- the Cancer Prevention & Research Institute of Texas (RR180035 & RP240392)
- the Appendiceal Cancer Pseudomyxoma Peritonei Research Foundation (N/A)
This publication has 40 references indexed in Scilit:
- 799P Fruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a phase Ib/II studyAnnals of Oncology, 2025
- Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE studyESMO Open, 2025
- Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionalityAnnals of Oncology, 2024
- Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal CancerJAMA Network Open, 2023
- Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastasesEuropean Journal of Cancer, 2023
- PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategiesCancer Immunology, Immunotherapy, 2023
- Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior ChemotherapyJAMA Oncology, 2023
- Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyeClinicalMedicine, 2023
- Immune Checkpoint Inhibitors in pMMR/MSS Colorectal CancerJournal of Gastrointestinal Cancer, 2023
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022